July 09, 2025

Once-Weekly Combo Injection Cuts Weight by 20% 

A large 68-week clinical trial found that a once-weekly combination injection of cagrilintide and semaglutide led to significant and sustained weight loss in adults with overweight or obesity, with over half achieving at least 20% weight reduction.

Conexiant

July 07, 2025

Cagrilintide–Semaglutide Yields Weight, A1c Gains

Once-weekly cagrilintide–semaglutide significantly reduced weight and improved glycemic control in adults with type 2 diabetes in the REDEFINE 2 trial.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 27, 2025

CGM Boosts Wound Healing, Lowers A1c: Study

Short-term CGM use improved A1c, wound healing, and reduced ED visits in diabetic foot patients, per data from ADA’s 85th Scientific Sessions.

Conexiant

June 27, 2025

Ecnoglutide Shows Strong Weight Loss in Trial

A once-weekly GLP-1 receptor agonist, ecnoglutide, led to significant and sustained weight loss in a large study of adults with overweight or obesity, with favorable safety outcomes reported at the ADA’s 85th Scientific Sessions.

Conexiant

June 25, 2025

Combo Obesity Therapy Preserves Muscle, Reduces Fat

A new combination therapy of semaglutide and bimagrumab helped patients lose more fat while preserving muscle mass, while a novel biosensor may help track muscle loss during obesity treatment.

Conexiant

June 24, 2025

Liraglutide Linked to Fewer Migraine Days

A small observational study found that liraglutide, a GLP-1 receptor agonist typically used to treat diabetes and support weight loss, significantly reduced migraine frequency in adults with a BMI of 30 or higher—independent of weight change.

Conexiant

June 23, 2025

Gut Microbiome May Hold Key to Avoiding Chemotherapy-Related Cardiotoxicity in Patients With Breast Cancer

A healthy gut microbiome prior to chemotherapy could help protect against cardiotoxicity as a result of breast cancer therapy, according to findings presented at the European Society of Cardiology (ES...

The ASCO Post

May 02, 2024

AACR 2024: Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

The combination of adagrasib and cetuximab may show clinical activity and promising survival outcomes in patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer.

Conexiant